Table 2
Tabulated summary of study schedule
| Enrolment T0 | Baseline T1 | FU3m T2 | FU6m T3 | |
| Eligibility screen | X | |||
| Informed consent | X | |||
| Allocation | X | |||
| PATHway intervention |
| |||
| Usual care (control) intervention |
| |||
| Assessments | ||||
| Physical activity | X | X | X | |
| Demographic characteristics | X | X | ||
| Health-related physical fitness | ||||
| CPET | X | X | X | |
| Muscle strength and flexibility | X | X | X | |
| Quality of the vascular system | X | X | X | |
| Blood sampling | X | X | ||
| Body composition | X | X | X | |
| Health-related QoL and psychosocial well-being | ||||
| PHQ-9 | X | X | X | |
| EQ-5D-5L questionnaire | X | X | x | |
| SF-36 questionnaire | X | X | X | |
| Exercise self-efficacy scale | X | X | X | |
| Medication adherence | X | X | X | |
| Exercise barriers | X | X | X | |
| Perceived stress scale | X | X | X | |
| ENRICHD | X | X | X | |
| Satisfaction/usability tests | X | |||
| Resource use data collection | X | X | X | |
| Safety monitoring | ||||
| Three-day ECG Holter monitoring | X | X | X | |
| Adverse event reporting |
| |||
| Process evaluation (assessment of DSS) | ||||
| Validation of DSS outcomes captured in reports by clinical experts | X | X | X | |
Satisfaction/usability test will only be performed in the intervention group.
CPET, cardiopulmonary exercise test; DSS, decision support system; ENRICHD, Enhancing Recovery In Coronary Heart Disease; EQ-5D-5L, EuroQol-Five Dimensions-Five Levels Questionnaire; PHQ-9, Patient Health Questionnaire 9; QoL, Quality of Life; SF-36, Short Form 36; T, timepoint.